arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

[George71]

"The combination of an arenaviral immunotherapy with a 4-1BB agonistic antibody resulted in complete tumor rejection in 30 percent of mice following treatment. Importantly, improved tumor control and cure rates of up to 50 percent were also observed with a 4-1BB ligand which was integrated into the arenaviral vector.

A separate preclinical analysis presented at AACR (abstract #3298) offered additional evidence of potential combination with other modalities. In this analysis, replicating arenaviral immunotherapy was sequentially combined with adoptively transferred TCR transgenic T cells, which resulted in tumor cures in all mice receiving combination therapy, with 100 percent survival at the end of the experiment (60 days after administration)."

finance.yahoo.com/news/data...

[j-o-h-n]

Of mice and men............... Hey Lennie!!! Where you hiding?....

Good Luck, Good Health and Good Humor.

j-o-h-n Thursday 04/14/2022 6:22 PM DST